Clinical verification of 18F-DCFPyL PET-detected lesions in patients with biochemically recurrent prostate cancer

202013 citationsJournal Articlegold Open Access

Authors

Dennie Meijer · Amsterdam University Medical Centers

B.H.E. Jansen · Amsterdam University Medical Centers

Maurits Wondergem · Noordwest Ziekenhuisgroep

Yves J. L. Bodar · Amsterdam University Medical Centers

Sandra Srbljin · Zaans Medisch Centrum

Annelies Vellekoop · Ziekenhuis Amstelland

Bram Keizer

Abstract

In this study, the clinical verification of 18F-DCFPyL PET-positive lesions in patients with BCR was performed. Diagnostic certainty of PET-detected lesions increases in the presence of characteristic abnormalities on CT, when SUVpeak is ≥3.5, when PSA-levels exceed 2.0 ng/mL or in patients with more than two PET-positive lesions.

Topics & Keywords

Prostate Cancer Treatment and Research Prostate Cancer Diagnosis and Treatment Urologic and reproductive health conditions

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: PLoS ONE

Volume 15, Issue 10, pp. e0239414-e0239414

DOI: 10.1371/journal.pone.0239414

Field-Weighted Citation Impact: 0.89